

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427

Status	RECRUITING
Phase	Not Applicable
Sponsor	Beth Israel Deaconess Medical Center
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (8)

- Male (physiological);
- Age \geq 50;
- Eligible for treatment with 5ARI therapy;
- Presence of lower urinary tract symptoms secondary to BPH;
- Prostate size \geq 40cc by digital rectal examination;
- ... and 3 more (see full listing online)

Exclusion (7)

- Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);
- Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;
- Current urinary tract infection;
- Previous pelvic radiation;
- Previous treatment with demethylating drugs;
- ... and 2 more (see full listing online)

Locations (1 total)

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States